Ignite Creation Date:
2024-05-06 @ 11:56 AM
Last Modification Date:
2024-10-26 @ 12:51 PM
Study NCT ID:
NCT03631407
Status:
COMPLETED
Last Update Posted:
2022-07-12
First Post:
2018-08-09
Brief Title:
Safety and Efficacy of Vicriviroc MK-7690 in Combination With Pembrolizumab MK-3475 in Participants With AdvancedMetastatic Microsatellite Stable MSS Colorectal Cancer CRC MK-7690-046
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Study Overview
Official Title:
A Phase 2 Trial to Evaluate the Safety and Efficacy of Vicriviroc MK-7690 in Combination With Pembrolizumab MK-3475 in Participants With AdvancedMetastatic Microsatellite Stable MSS Colorectal Cancer CRC
Status:
COMPLETED
Status Verified Date:
2022-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This trial will evaluate the safety and efficacy of vicriviroc MK-7690 at 2 dose levels in combination with pembrolizumab MK-3475 in participants with advancedmetastatic microsatellite stable MSS colorectal cancer CRC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| MK-7690-046 | OTHER | Merck | None |